» Authors » Evgenia Isachenko

Evgenia Isachenko

Explore the profile of Evgenia Isachenko including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 71
Citations 544
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
11.
Chen J, Isachenko E, Wang W, Du X, Wang M, Rahimi G, et al.
Biopreserv Biobank . 2021 Dec; 20(6):529-539. PMID: 34936496
A functional artificial ovary is a promising strategy to recover fertility and restore endocrine function in cancer patients. The aim of this study is to optimize the follicle isolation protocol...
12.
Petrushko M, Yurchuk T, Todorov P, Hristova E, Piniaiev V, Isachenko E, et al.
Cryobiology . 2021 Oct; 103:39-44. PMID: 34606824
Data about cryoprotectant-free cryopreservation of human ICSI spermatozoa are limited. The aim of this investigation was to compare two technologies for cryopreservation of spermatozoa from men with oligoasthenoteratozoospermia: standard conventional...
13.
Isachenko V, Isachenko E, Mallmann P, Rahimi G
Cryobiology . 2021 Sep; 103:1-6. PMID: 34571024
Cryopreservation and re-transplantation of ovarian tissue after anticancer treatment is important medical technology. Today, during a pandemic, the risk of contamination of transplanted cells with SARS-CoV-2 virus is extremely high....
14.
Kumar P, Wang M, Isachenko E, Rahimi G, Mallmann P, Wang W, et al.
Front Cell Dev Biol . 2021 Jul; 9:672862. PMID: 34277615
Mitochondria-targeted antioxidants have great potential to counterbalance the generated reactive oxygen species (ROS) because they cross the inner membrane of the mitochondria. Still, their use was not reported in vitrified...
15.
Salama M, Isachenko E, Rahimi G, Mallmann P, Isachenko V
Oncology (Williston Park) . 2021 Jun; 35(6):332-334. PMID: 34147055
A nulliparous woman, age 25 years, had received a diagnosis of non-Hodgkin lymphoma (NHL) and now presented with stage IIA diffuse large B-cell lymphoma (DLBCL). According to her hematological oncologist's...
16.
Chen J, Todorov P, Isachenko E, Rahimi G, Mallmann P, Isachenko V
Hum Fertil (Camb) . 2021 Mar; 25(4):651-661. PMID: 33648431
The proportion of cancer patients that survive is increasing because of improvements in cancer therapy. However, some cancer treatments, such as chemo- and radio-therapies, can cause considerable damage to reproductive...
17.
Diaz-Jimenez M, Wang M, Wang W, Isachenko E, Rahimi G, Kumar P, et al.
Cell Tissue Bank . 2021 Feb; 23(1):17-29. PMID: 33608835
Cryoprotectant-free vitrification is a common method for spermatozoa cryopreservation by direct plunging into liquid nitrogen. However, the commercial liquid nitrogen could be potentially contaminated by microorganisms. Warming temperature plays an...
18.
Wang W, Salama M, Todorov P, Spitkovsky D, Isachenko E, Bongaarts R, et al.
Cell Tissue Bank . 2021 Jan; 22(3):487-498. PMID: 33486657
As recently announced by the American Society for Reproductive Medicine (ASRM), human ovarian tissue cryopreservation is an established option for fertility preservation in prepubertal girls and young women undergoing gonadotoxic...
19.
Wang W, Todorov P, Isachenko E, Rahimi G, Mallmann P, Wang M, et al.
Eur J Obstet Gynecol Reprod Biol . 2021 Jan; 258:258-264. PMID: 33485262
Objective: Primordial follicles in premature ovarian failure (POF) patients are very difficult to be activated spontaneously, so that mature oocytes are difficult to be obtained for in vitro fertilization. The...
20.
Wang M, Todorov P, Isachenko E, Rahimi G, Wang W, von Brandenstein M, et al.
Cryobiology . 2021 Jan; 99:95-102. PMID: 33422478
The protocol of aseptic cryoprotectant-free vitrification on human spermatozoa is well documented. However, data about the effect of permeable cryoprotectants at this procedure is limited. Presented study aimed to test...